Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer - a narrative review

Paweł Szponar; Piotr Petrasz; Katarzyna Brzeźniakiewicz-Janus; Tomasz Drewa; Piotr Zorga; Jan Adamowicz

doi:10.3389/fonc.2023.1239118

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer - a narrative review

Front Oncol. 2023 Nov 16:13:1239118. doi: 10.3389/fonc.2023.1239118. eCollection 2023.

Authors

Paweł Szponar^#¹, Piotr Petrasz^#¹, Katarzyna Brzeźniakiewicz-Janus², Tomasz Drewa³, Piotr Zorga⁴, Jan Adamowicz³

Affiliations

¹ Department of Urology and Urological Oncology, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland.
² Department and Clinic of Hematology, Oncology and Radiotherapy of the University of Zielona Góra, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland.
³ General and Oncological Urology Clinic, University Hospital No. 1 Dr. Antoni Jurasz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.
⁴ Clinical Department of Nuclear Medicine with a PET/CT Laboratory of the University of Zielona Góra, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland.

^# Contributed equally.

Abstract

Introduction: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature on the therapeutic isotopes specific for PSMA.

Methods: We performed a scoping literature review of PubMed from January 1996 to December 2022.

Results: 98 publications were selected for inclusion in this review. The studies contained in publications allowed to summarize the data on pharmacokinetics, therapeutic effects, side effects and the medical use of 225Ac and 177Lu radionuclides. The review also presents new research directions for specific PSMA radionuclides.

Conclusion: Radioligand targeted therapy is a new and promising concept where Lu-177-PSMA-617 have promising outcomes in treatment according to standard of care.

Keywords: 177Luthtet; 225Actinum; CRPC; PET-PSMA; radionuclide.

Publication types

Review

Grants and funding

The authors declare that this study received funding from Department of Urology and Urological Oncology, Multidisciplinary Regional Hospital in Gorzów Wielkopolski, Poland and Department of General and Oncologic Urology, Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Poland. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of the article, or the decision to submit it for publication.